Technology | EP Mapping and Imaging Systems | July 01, 2019

VIVO 3-D Cardiac Mapping System Cleared by FDA

New non-invasive cardiac imaging system from Catheter Precision offers higher accuracy

VIVO 3-D Cardiac Mapping System Cleared by FDA

July 1, 2019 — Catheter Precision Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared its new VIVO (View into Ventricular Onset) system for market release in the United States. VIVO is a pre-procedure planning tool that offers 3-D cardiac mapping to aid in localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to electrophysiology studies. The novel VIVO system uses magnetic resonance imaging (MRI) or a computed tomography (CT) scan along with a standard 12-lead ΕCG to computer-generate color-coded 3-D mapping images of the heart to indicate the area of earliest activation.

The VIVO system consists of a handheld 3-D camera, and an off-the-shelf laptop computer with proprietary software. Using a 3-D photograph of the patient's chest, an MRI or CT (DICOM image), and a standard 12-lead ECG, the system generates a 3-D rendering of the patient's heart with superimposed color coding to indicate the area of earliest activation. VIVO uses lead positions, the chest photograph and DICOM data to determine the precise spatial relationships involved and, in that way, provide latest-generation cardiac mapping that can be used by a physician prior to conducting an electrophysiology study and subsequent ablation. The VIVO system has been shown to be 100 percent accurate (95 percent CI: 93.6 percent, 100 percent) in a prospective multi-center clinical trial. 

"VIVO is an important advance for patients who may require a cardiac ablation to better understand their irregular heart rhythms," said Hari Tandri, M.D., from Johns Hopkins University Hospital. "It is easy to use, fits into our standard workflow and is not invasive. Knowing the arrhythmia foci in advance should reduce mapping time, potentially saving procedure time and cost.  My experience with the VIVO to date has shown it to be an accurate, easy-to-use system that has the potential to significantly improve 3-D cardiac mapping technology for ventricular arrhythmia mapping."

For more information: www.catheterprecision.com

Related Content

Biosense Webster Announces Initial Results From First-in-Human QDOT-FAST Study
News | Ablation Systems | May 16, 2019
Johnson & Johnson Medical Devices Companies announced that Biosense Webster, Inc.’s QDot Micro catheter...
CardioFocus Announces Results From HeartLight X3 Ablation System Pivotal Study
News | Ablation Systems | May 16, 2019
CardioFocus Inc. announced the presentation of results from its pivotal confirmatory study evaluating the HeartLight X3...
New Global Consensus Statement Addresses Catheter Ablation of Ventricular Arrhythmias
News | Ablation Systems | May 14, 2019
The Heart Rhythm Society (HRS) in partnership with three other professional societies issued an international consensus...
Netherlands Hospital to Install State-of-the-Art MRI Ablation Center
News | Ablation Systems | May 13, 2019
Imricor announced the signing of a commercial agreement with the Haga Hospital in The Hague, Netherlands to outfit a...
A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beam will ablate for a noninvasive pulmonary vein isolation procedure. Varian acquires, buys, purchases Cyberheart.

A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beams will ablate for a noninvasive pulmonary vein isolation procedure to treat an arrhythmia.

Feature | Ablation Systems | May 10, 2019 | Dave Fornell, Editor
May 10, 2019 — Radiation oncology vendor Varian announced it acquired the start-up company CyberHeart, which has deve
Ablation Reduces Risk of Dementia in Patients With AFib and Carotid Artery Disease
News | Ablation Systems | May 08, 2019
Even though many medical practitioners may opt not to perform procedures on higher-risk patients, new research finds it...
CardioFocus Announces European CE Mark Approval Of HeartLight X3 System
News | Ablation Systems | April 16, 2019
CardioFocus Inc. announced the European CE Mark approval of the HeartLight X3 Endoscopic Ablation System.
First Patient Treated With QDot Micro Ablation Catheter
News | Ablation Systems | February 04, 2019
Biosense Webster has enrolled and treated the first patient in its U.S. Investigational Device Exemption (IDE) study...
FDA Approves TactiCath Contact Force Ablation Catheter, Sensor Enabled
Technology | Ablation Systems | January 21, 2019
Abbott announced U.S. Food and Drug Administration (FDA) approval of the TactiCath Contact Force Ablation Catheter,...
First Patient Treated in STELLAR Atrial Fibrillation IDE Study
News | Ablation Systems | November 30, 2018
Johnson & Johnson Medical Devices Companies announced that Biosense Webster Inc. has enrolled and treated the first...
Overlay Init